Switzerland· 68001005
Verquvo 5.0 mg, Filmtabletten
A vericiguat product containing vericiguatum, registered in Switzerland by Bayer (Schweiz) AG and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 15 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Vericiguat is registered in 15 of 19 countries.
Countries holding a registration under ATC C01DX22 (vericiguat), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 9 of them publish a price we can compare per daily dose
Vericiguat · ATC C01DX22
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of vericiguat costs, country by country.
Normalised to the WHO defined daily dose (10 mg), so markets compare like for like.
- Switzerland: $12.83 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Vericiguat · price per daily dose (10 mg)
USD · FX 28 Sept 2026
- CH Switzerland$12.83
- ES Spain$9.99
- IT Italy$9.50
The record
At a glance
Swissmedic (Switzerland)- Active substance
- vericiguatum
- Manufacturer
- Bayer (Schweiz) AG
- Country
- Switzerland (CH)
- ATC code
- C01DX22
- ATC class
- Vericiguat
- Defined daily dose
- 10 mg, O
- Swissmedic category
- B
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680680010051Blist 98 StkCHF 282.05
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Vericiguat in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaVERQUVOBayer AG, Leverkusen
- SpainVERQUVO 5 MG COMPRIMIDOS RECUBIERTOS CON PELICULABayer Ag
- IcelandVerquvoBayer AG*
- NetherlandsVerquvo 5 mg filmomhulde tablettenBayer AG
- NorwayVerquvoBayer AG
- PolandVerquvoBayer AG
- SwedenVerquvo 5 mg Filmdragerad tablettBayer AG
- BelgiumVerquvo 5 mgBayer
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Verquvo
- Liechtenstein · Verquvo
- Norway · Verquvo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ca9f6521-ab4e-498b-9082-0ebc16900b62 GET /v1/drugs/ca9f6521-ab4e-498b-9082-0ebc16900b62?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "vericiguatum 5 mg",
"valid_from": "2025-03-01",
"limitations": "[{\"description\":\"Zur Behandlung erwachsener Patienten mit einer rekompensierten symptomatischen chronischen Herzinsuffizienz der NYHA Klassen II-IV, deren linksventrikuläre Auswurffraktion (LVEF) vor Behandlung mit Verquvo ≤ 40% beträgt und die – trotz vorab optimal eingestellter Basistherapie, die mindestens eine zuvor stabil eingestellte Dosis eines ARNI (Angiotensin-Rezeptorblocker-Neprilysininhibitor), sowie eines Betablockers, eines Mineralokortikoidrezeptorantagonisten (MRA) und eines SGLT2-Inhibitors enthielt - eine kürzlich aufgetretene Dekompensation hatten, die eine i.v.-Therapie erforderte.<br>\\n<br>\\nZudem kann Verquvo bei erwiesener Intoleranz oder Kontraindikation gegenüber einer Substanzklasse der Basistherapien die bestehende Herzinsuffizienztherapie nach Dekompensation ergänzen.<br>\\n<br>\\nVor Initiierung der Behandlung mit Verquvo muss eine ausreichende Stabilisierung nach kürzlich aufgetretener Dekompensation sichergestellt werden, insbesondere bei Patienten mit stark erhöhten NT-proBNP-Spiegeln. Die klinische Stabilisierung schliesst die Behandlung der Volumenüberladung mittels intensivierter (intravenöser) Diuretika-Therapie und die Optimierung der Behandlung mit anderen Standardtherapeutika für Herzinsuffizienz ein.<br>\\n<br>\\nDie Erstverordnung von Verquvo darf ausschliesslich durch einen Facharzt für Kardiologie erfolgen.<br>\\n<br>\",\"costApproval\":null,\"indication\":\"\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2025-03-01\"}]",
"galenic_form": "Filmtabl 5 mg",
"therapeutic_area": null,
"sl_inclusion_date": "2023-03-01",
"self_retention_pct": 10
}See everything about vericiguat.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.